Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 87 of 513 for:    ESCITALOPRAM AND Serotonin Uptake

Progression Delaying Effect of Escitalopram in Alzheimer's Disease (ESAD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00702780
Recruitment Status : Completed
First Posted : June 20, 2008
Results First Posted : June 13, 2014
Last Update Posted : June 13, 2014
Sponsor:
Collaborator:
H. Lundbeck A/S
Information provided by (Responsible Party):
Dong Young Lee, Seoul National University Hospital

Study Type Interventional
Study Design Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition Alzheimer's Disease
Interventions Drug: escitalopram
Drug: placebo
Enrollment 74
Recruitment Details  
Pre-assignment Details  
Arm/Group Title Escitalopram Placebo
Hide Arm/Group Description escitalopram 20mg qd placebo 20mg qd
Period Title: Overall Study
Started 37 37
Completed 28 29
Not Completed 9 8
Arm/Group Title Escitalopram Placebo Total
Hide Arm/Group Description escitalopram 20mg qd placebo 20mg qd Total of all reporting groups
Overall Number of Baseline Participants 28 29 57
Hide Baseline Analysis Population Description
[Not Specified]
Age, Continuous  
Mean (Standard Deviation)
Unit of measure:  Years
Number Analyzed 28 participants 29 participants 57 participants
74.33  (7.12) 74.82  (9.19) 74.58  (8.17)
Sex: Female, Male  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 28 participants 29 participants 57 participants
Female
15
  53.6%
21
  72.4%
36
  63.2%
Male
13
  46.4%
8
  27.6%
21
  36.8%
1.Primary Outcome
Title % Change of Hippocampus Volume
Hide Description [Not Specified]
Time Frame 52 weeks
Hide Outcome Measure Data
Hide Analysis Population Description
The analysis was performed for per-protocol (PP) population, which included participants who had both baseline and follow-up MRI scan suitable for analysis.
Arm/Group Title Escitalopram Placebo
Hide Arm/Group Description:
escitalopram 20mg qd
placebo 20mg qd
Overall Number of Participants Analyzed 28 29
Mean (Standard Deviation)
Unit of Measure: percentage of change
-7.63  (7.32) -7.28  (5.76)
2.Primary Outcome
Title % Change of Whole Brain Volume
Hide Description [Not Specified]
Time Frame 52 weeks
Hide Outcome Measure Data
Hide Analysis Population Description
The analysis was performed for per-protocol (PP) population, which included participants who had both baseline and follow-up MRI scan suitable for analysis.
Arm/Group Title Escitalopram Placebo
Hide Arm/Group Description:
escitalopram 20mg qd
placebo 20mg qd
Overall Number of Participants Analyzed 28 29
Mean (Standard Deviation)
Unit of Measure: percentage of change
-3.27  (2.69) -2.30  (3.08)
Time Frame Baseline, and 2, 4, 8, 16, 28, 40, 52 weeks after baseline.
Adverse Event Reporting Description [Not Specified]
 
Arm/Group Title Escitalopram Placebo
Hide Arm/Group Description Escitalopram 20mg qd Placebo 20mg qd
All-Cause Mortality
Escitalopram Placebo
Affected / at Risk (%) Affected / at Risk (%)
Total   --/--   --/-- 
Show Serious Adverse Events Hide Serious Adverse Events
Escitalopram Placebo
Affected / at Risk (%) Affected / at Risk (%)
Total   2/37 (5.41%)   3/37 (8.11%) 
Gastrointestinal disorders     
Vomiting   0/37 (0.00%)  1/37 (2.70%) 
Hepatobiliary disorders     
Jaundice   1/37 (2.70%)  0/37 (0.00%) 
Respiratory, thoracic and mediastinal disorders     
Pneumonia   0/37 (0.00%)  1/37 (2.70%) 
Social circumstances     
Death by traffic accident   1/37 (2.70%)  0/37 (0.00%) 
Vascular disorders     
Cerebral hemorrhage   0/37 (0.00%)  1/37 (2.70%) 
Indicates events were collected by systematic assessment
Show Other (Not Including Serious) Adverse Events Hide Other (Not Including Serious) Adverse Events
Frequency Threshold for Reporting Other Adverse Events 0%
Escitalopram Placebo
Affected / at Risk (%) Affected / at Risk (%)
Total   13/37 (35.14%)   7/37 (18.92%) 
Endocrine disorders     
hypoglycemia   1/37 (2.70%)  0/37 (0.00%) 
Gastrointestinal disorders     
vomiting   0/37 (0.00%)  1/37 (2.70%) 
anorexia   1/37 (2.70%)  1/37 (2.70%) 
abdominal pain   0/37 (0.00%)  1/37 (2.70%) 
diarrhea   1/37 (2.70%)  0/37 (0.00%) 
constipation   0/37 (0.00%)  1/37 (2.70%) 
General disorders     
somnolence   1/37 (2.70%)  0/37 (0.00%) 
Injury, poisoning and procedural complications     
fall   0/37 (0.00%)  1/37 (2.70%) 
Neoplasms benign, malignant and unspecified (incl cysts and polyps)     
cancer   1/37 (2.70%)  1/37 (2.70%) 
Nervous system disorders     
dizziness   4/37 (10.81%)  0/37 (0.00%) 
tremor   1/37 (2.70%)  0/37 (0.00%) 
Psychiatric disorders     
violent behavior   1/37 (2.70%)  0/37 (0.00%) 
Renal and urinary disorders     
urinary incontinence   1/37 (2.70%)  0/37 (0.00%) 
Respiratory, thoracic and mediastinal disorders     
cough   1/37 (2.70%)  0/37 (0.00%) 
bronchitis   0/37 (0.00%)  1/37 (2.70%) 
Indicates events were collected by systematic assessment
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
Results Point of Contact
Name/Title: Young Min Choe
Organization: Seoul National University Hospital
Phone: 82-2-2072-1730
Responsible Party: Dong Young Lee, Seoul National University Hospital
ClinicalTrials.gov Identifier: NCT00702780     History of Changes
Other Study ID Numbers: SNUDC001
First Submitted: June 15, 2008
First Posted: June 20, 2008
Results First Submitted: April 10, 2014
Results First Posted: June 13, 2014
Last Update Posted: June 13, 2014